We can’t show the full text here under this license. Use the link below to read it at the source.
The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis
Psilocybin's effects on psychological distress in cancer patients: a review and analysis
AI simplified
Abstract
significantly reduced depressive symptoms in cancer patients, with a of -2.87 on the Beck Depression Inventory.
- In randomized controlled trials, psilocybin showed strong effects on depressive symptoms as measured by the -Depression subscale, with a standardized mean difference of -2.97.
- Short-term follow-up (2-5 weeks) indicated significant reductions in depressive and anxiety symptoms, with standardized mean differences of -1.17 for the Beck Depression Inventory and -1.99 for the Hospital Anxiety and Depression Scale-Anxiety subscale.
- Long-term follow-up (6 months) demonstrated sustained benefits on depressive symptoms, with a standardized mean difference of -2.60 on the Beck Depression Inventory.
- Improvements in quality of life and spiritual well-being were noted after psilocybin treatment, as measured by the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being scale.
- Findings on anxiety outcomes were mixed, with no significant change observed in the Hospital Anxiety and Depression Scale-Anxiety subscale.
AI simplified
Key numbers
-2.87
Decrease in Depression (BDI)
from randomized controlled trials
-1.17
Short-term Depression Reduction
over 2-5 weeks
-2.60
Long-term Depression Reduction
from long-term follow-up